AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
3.300
+0.020 (0.61%)
Apr 13, 2026, 4:00 PM EDT - Market closed
AC Immune Employees
As of December 31, 2025, AC Immune had 122 total employees, including 90 full-time and 32 part-time employees. The number of employees decreased by 50 or -29.07% compared to the previous year.
Employees
122
Change (1Y)
-50
Growth (1Y)
-29.07%
Revenue / Employee
$36,934
Profits / Employee
-$728,210
Market Cap
327.36M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 122 | -50 | -29.07% | 90 | 32 |
| Dec 31, 2024 | 172 | 11 | 6.83% | 133 | 39 |
| Dec 31, 2023 | 161 | 5 | 3.21% | 133 | 28 |
| Dec 31, 2022 | 156 | 7 | 4.70% | 126 | 30 |
| Dec 31, 2020 | 149 | 17 | 12.88% | 125 | 24 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Cabaletta Bio | 156 |
| Neurogene | 131 |
| Prelude Therapeutics | 79 |
| Candel Therapeutics | 55 |
| Immuneering | 53 |
| Surrozen | 44 |
| DiaMedica Therapeutics | 35 |
ACIU News
- 6 days ago - AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly - GlobeNewsWire
- 4 weeks ago - AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 4 months ago - AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - Benzinga
- 4 months ago - AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease - GlobeNewsWire
- 5 months ago - AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 6 months ago - First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine - GlobeNewsWire
- 8 months ago - AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 1 year ago - AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire